Are peptides legal in the US?

Most strength peptides in the US occupy a gray zone: not FDA-approved for human use, not Drug Enforcement Administration scheduled, sold as research chemicals with non-human-use disclaimers. Possession of these peptides is largely unregulated at the federal level. The regulatory pressure point is sale and marketing for human use — not the buyer side. A handful of peptides have specific status: Tesamorelin is FDA-approved (HIV-associated lipodystrophy, brand Egrifta); Sermorelin has historical compounding pathways; BPC-157 was specifically rejected for 503A compounding by FDA in November 2023.

The three regulatory categories

Strength peptides fall into one of three buckets in the US:

The third category is where most strength peptides sit. The FDA hasn't approved them, but they aren't on a controlled-substance schedule either. Vendors sell them with research-use disclaimers; users buy them and dose themselves; the FDA's enforcement focus is on vendors marketing for human use, not on individual users.

What "research chemical" actually means legally

A research chemical sold for non-human research is in a regulatory category that is neither approved nor prohibited. The relevant rules:

• No FDA approval — the molecule has not gone through the new-drug approval process for human use
• No DEA schedule — these aren't controlled substances, so possession isn't a federal drug-possession offense
• FDCA section 301 — introducing an unapproved new drug into interstate commerce for human use is a violation, which is why vendors disclaim human use
• State law variation — some states have additional restrictions; federal law isn't the only layer

The structure means a vendor can legally sell a research chemical for research purposes; selling the same chemical for human use is a different action with different regulatory exposure. Buyers don't bear that exposure in the same way — but state laws, prescription requirements, and importation rules can add complexity.

The BPC-157 503A rejection (November 2023)

This is the most-cited recent regulatory event in the strength peptide space. In November 2023, the FDA's Pharmacy Compounding Advisory Committee voted against adding BPC-157 to the 503A bulks list — meaning compounding pharmacies cannot legally compound BPC-157 for individual patients with prescriptions. The committee cited insufficient safety data and unclear manufacturing standards. The vote did not make BPC-157 illegal to possess; it closed off the prescription-compounding route. BPC-157 remains available only as a research chemical from research-chem vendors. See the FDA BPC-157 503A status for the full timeline.

The peptides with actual prescription pathways

A handful of strength-adjacent peptides can be legitimately prescribed:

Off-label prescribing is a different category — physicians can prescribe approved drugs off-label, but they cannot prescribe drugs that aren't approved at all. A "BPC-157 prescription" from a US physician is not a legal pharmaceutical product since the November 2023 ruling.

Possession vs. sale vs. importation

Three distinct legal questions, often conflated:

State laws can add layers — some states regulate certain peptides as controlled substances or restrict telemedicine prescribing. The federal landscape is the floor, not the ceiling.

What "legal" really means in practice

For an individual user in the US, the practical regulatory situation:

• Buying research-chem peptides for personal research isn't a federal crime
• Vendors face regulatory risk if they market for human use; users generally don't
• No prescription is required for research-chem peptides because none is available
• For prescribable peptides (Tesamorelin, Sermorelin), going through a physician and compounding pharmacy is the legitimate path
• State laws vary — check yours specifically

This isn't legal advice. It's a description of the regulatory landscape as it stands. For jurisdiction-specific guidance, talk to a lawyer familiar with FDA and state pharmacy law.

The international comparison

The US is comparatively permissive for research-chem peptides. Most peer countries are stricter:

For region-specific detail, see international legal status.

Bottom line

The honest summary: most strength peptides are research chemicals in the US — not approved, not scheduled, sold for non-human research, possessed by individuals without specific regulatory exposure. The vendor side is where the legal weight sits. The peptides that can be legitimately prescribed are a small subset (mainly Tesamorelin, plus Sermorelin in some jurisdictions). Talk to a lawyer for jurisdiction-specific advice on your situation.

Related questions

• Can I get peptides through customs?
• Can I get a prescription for BPC-157?
• Do I need a doctor for peptides?
• FDA 503A and 503B framework